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Background: In clopidogrel treated patients undergoing PCI, high platelet reactivity (HPR) is associated with a higher risk for stent thrombosis 
(ST). Prasugrel may be advantageous over clopidogrel especially in HPR patients. Here, we report the results of a 5 year-experience of routine 
platelet function (PF) testing for guidance of antiplatelet treatment in PCI-treated patients. 
Methods: ST risk was compared between two consecutively recruited cohorts. One cohort (n=428) of HPR patients without treatment adjustment 
stems from a trial including 2533 patients that we conducted between Feb 2007-Dec 2008. The second cohort (n=143) was consecutively recruited 
between Jan 2009-Oct 2011 and includes HPR patients with a treatment switch from clopidogrel to prasugrel in a setting of routine PF testing. 
Platelet aggregation (PA) was tested on a Multiplate analyzer and repeated clopidogrel loading doses (LD) were given in the majority of patients 
before switching to prasugrel. The primary outcome was the incidence of early ST (definite or probable). 
Results: In the 143 patients with treatment adjustment, on-clopidogrel PA was 617 ± 200 AU x min before switching to prasugrel and 184 ± 150 
AU x min afterwards, with 7 (5%) patients continuing to show HPR on prasugrel. The incidence of ST was 4-fold higher in the HPR cohort without 
treatment adjustment as compared to the HPR cohort with adjustment (12 (2.8%) vs. 1 (0.7%) ST; adjusted p=0.036). In a multivariate logistic 
regression model with ST as the dependent variable and treatment adjustment (switch from clopidogrel to prasugrel) as well as other variables 
(diabetes, age, gender, BMI, smoking, STEMI, cardiopulmonary reanimation) as independent variables, adjustment was found to be an independent 
predictor for a lower ST risk (OR 0.08, 95% CI 0.01-0.84). 
Conclusion: Routine PF testing is useful for guidance of tailored antiplatelet treatment and switching to prasugrel markedly reduces ST risk in HPR 
patients on clopidogrel. Following repeated clopidogrel LDs and prasugrel LD, a small proportion of patients continue to show HPR on prasugrel. 
Further studies are needed to establish algorithms for tailored antiplatelet treatment in PCI-treated patients.
